AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

AbbVie Inc.NYSE: ABBV

Net Margin · Q3 FY2026 · quarter ended Sep 2026

Net margin widens to 24.3%

Net margin was 24.3% in Q3 FY2026, up 23.1 pp from a year earlier. On a trailing-twelve-month basis it was 15.7%, up 11.7 pp year over year. Over 3 fiscal years it narrowed by 13.5 pp.

Context

  • Net margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 19 analysts of 36.6% for the fiscal year ending Dec 2026, up from 6.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
24.3%+3.0 pp QoQ
Last fiscal yearDec 2025
6.9%-0.7 pp YoY
LTMSep 2026
15.7%+11.7 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+23.1 pp+26.7 pp+3.6 pp
1 year-0.7 pp+29.7 pp+30.4 pp
3 years-13.5 pp+33.3 pp+46.7 pp
5 years+36.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
6.9%
Year-over-year change
-0.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ABBV compares with its peers on the latest reported figures

  • ABBV's LTM Sep 2026 net margin of 15.7% is the 7th highest of the 10 companies compared; the peer median is 17.7%.
  • Its year-over-year change of +11.7 pp is the highest of 10, against a peer median of +1.5 pp.
  • Over three fiscal years its change of -13.5 pp compares with a peer median of +3.6 pp.
ABBV Competitors Peer median
Net Margin for ABBV and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202633.5% +7.6 pp+9.8 pp
NVSNovartis AGLTM Jun 202622.9% -1.8 pp+9.6 pp
AMGNAmgen Inc.LTM Jun 202622.9% +4.0 pp-3.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202618.9% +8.3 pp+0.9 pp
AZNAstraZeneca PLCLTM Sep 202617.7% +1.5 pp+10.0 pp
JNJJohnson & JohnsonLTM Sep 202616.2% -11.1 pp+6.0 pp
ABBVAbbVie Inc.LTM Sep 202615.7% +11.7 pp-13.5 pp
GSKGSK plcLTM Jun 202614.5% +3.7 pp-33.5 pp
PFEPfizer Inc.LTM Jun 20266.8% -10.0 pp-18.6 pp
MRKMerck & Co., Inc.LTM Jun 20264.8% -21.0 pp+3.6 pp
Peer median (excluding ABBV) 17.7%+1.5 pp+3.6 pp

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.2B58.05B54.32B56.33B61.16B
Cost of Revenue17.45B17.41B20.42B16.9B18.2B
Gross Profit38.75B40.64B33.9B39.43B42.96B
Gross Margin69.0%70.0%62.4%70.0%70.2%
Research & Development8.05B6.51B7.68B12.79B9.1B
Selling, General & Admin12.35B15.26B12.87B14.75B14.01B
Operating Expenses20.83B22.52B21.15B30.29B22.87B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
EBITDA23.93B24.17B17.17B14.91B17.63B
EBITDA Margin42.6%41.6%31.6%26.5%28.8%
Operating Income17.92B18.12B12.76B9.14B20.09B
Operating Margin31.9%31.2%23.5%16.2%32.8%
Interest Income39M186M540M648M266M
Interest Expense2.42B2.23B2.22B2.81B2.89B
Other Income / Expenses(4.94B)(4.64B)(6.51B)(5.42B)(13.49B)
Income Before Tax12.99B13.48B6.25B3.72B6.6B
Pre-Tax Margin23.1%23.2%11.5%6.6%10.8%
Income Tax Expense1.44B1.63B1.38B(570M)2.36B
Net Income11.54B11.84B4.86B4.28B4.23B
Net Margin20.5%20.4%9.0%7.6%6.9%
EPS (Basic)6.486.652.732.402.37
EPS (Diluted)6.456.632.722.392.37
Weighted Avg Shares1.77B1.77B1.77B1.77B1.77B
Weighted Avg Shares (Diluted)1.78B1.78B1.77B1.77B1.77B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.